Compared side by side

Teriparatide vs abaloparatide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are daily bone-building shots that act on the same receptor, PTH1: teriparatide is a copy of the first 34 amino acids of human parathyroid hormone, and abaloparatide a 34-amino-acid peptide modelled on a related hormone, PTHrP. Both are FDA-approved for osteoporosis at high risk of fracture, teriparatide as Forteo since 2002 and abaloparatide as Tymlos since 2017, for up to 2 years in most people. In their main trials, teriparatide cut new spine fractures by 65%, and on abaloparatide they fell from 4.2% on placebo to 0.6% over 18 months.

Side by side

ComparedTeriparatideAbaloparatide
CategoryHealing & recoveryHealing & recovery
Also known asForteo, Bonsity, PTH 1-34, rhPTH(1-34), LY333334Tymlos, BA058
What it isA daily shot of the active part of parathyroid hormone (Forteo) that builds new bone, rather than only slowing bone loss as most osteoporosis drugs do.A daily shot (Tymlos) that builds new bone, a close relative of teriparatide modelled on a different natural hormone, PTHrP.
How it worksA bone-building copy of the first 34 amino acids of human parathyroid hormone (PTH), the active part of the 84-amino-acid hormone that controls calcium in bone and kidney. The pattern of exposure decides what it does: a short daily pulse stimulates the cells that build bone (osteoblasts) more than those that remove it, so new bone forms on the inner and outer surfaces, while a constant excess of PTH, as in an overactive parathyroid, breaks bone down. FDA-approved in 2002 (Forteo) for osteoporosis at high fracture risk in postmenopausal women, in men, and with long-term steroid use.A bone-building 34-amino-acid peptide modelled on PTHrP, the parathyroid-hormone-related peptide (76% the same as its active part, 41% the same as teriparatide's PTH). It activates the PTH1 receptor on bone cells, and a daily dose stimulates the bone-building cells, so new bone forms on the inner and outer surfaces. FDA-approved in 2017 for postmenopausal women with osteoporosis at high fracture risk, and later for men; it is the sibling of teriparatide, with one dose and the same 2-year limit.
Commonly reportedLittle day to day, sometimes joint pain, nausea, leg cramps or light-headedness after the first shots. FDA-approved since 2002, for up to 2 years in most people; some people also read about it for fracture healing, which the label does not cover.Redness where the shot goes in, and dizziness or a fast heartbeat for a while after the first doses. FDA-approved since 2017, for up to 2 years.
Studied rangeFDA label: 20 mcg, starting dose 20 mcg.FDA label: 80 mcg, starting dose 80 mcg.
How oftenDaily SubQDaily SubQ
Half-life~1 hour (FDA label)~1 hour (FDA label)
RouteSubQ injectionSubQ injection
Typical runThe label limits use to 2 years in a lifetime unless fracture risk stays or returns high. Its fracture trial ran a median of 19 months in women; the men's trial a median of 10 to 11 months.The label does not recommend more than 2 years in a lifetime; its fracture trial ran 18 months, followed in the trial by alendronate, which kept the lower fracture risk through 24 more months.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsJoint pain, pain, nausea, dizziness, leg cramps, light-headedness on standing (first doses), brief rise in blood calciumInjection site redness, dizziness, nausea, headache, palpitations, fatigue, high urine calcium

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Taking teriparatide or abaloparatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Teriparatide

  • Day 1–14 · 20 mcg The first shots, sitting down
  • Day 14–90 A short calcium pulse each day
  • Day 90–365 New bone, built in the background
  • Day 365–730 Fewer fractures, and the 2-year line

Every card for teriparatide, with its sources

Abaloparatide

  • Day 1–14 · 80 mcg The first shots, sitting down
  • Day 14–60 Redness where the shot goes in
  • Day 60–365 New bone, built in the background
  • Day 365–730 Fewer fractures, then the 2-year line

Every card for abaloparatide, with its sources

Questions people ask

How long do teriparatide and abaloparatide last?

The half-life of teriparatide is ~1 hour (FDA label). The half-life of abaloparatide is ~1 hour (FDA label).

How often are teriparatide and abaloparatide taken?

Teriparatide: daily SubQ. Route: SubQ injection. Abaloparatide: daily SubQ. Route: SubQ injection.

How are teriparatide and abaloparatide dosed in research?

The FDA label range for teriparatide is 20 mcg, with a 20 mcg starting dose. The FDA label range for abaloparatide is 80 mcg, with a 80 mcg starting dose.

What are the common side effects of teriparatide and abaloparatide?

For teriparatide, the library lists: joint pain, pain, nausea, dizziness, leg cramps, light-headedness on standing (first doses), brief rise in blood calcium. For abaloparatide: injection site redness, dizziness, nausea, headache, palpitations, fatigue, high urine calcium.

Each one in full

Track it in the app

PepVault for iPhone

Taking teriparatide or abaloparatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo